Chain Drug Review - Battle over Clarinex switch
January 12th, 2009 WASHINGTON–The National Consumers League (NCL) wants the Food and Drug Administration to keep Clarinex as a prescription-only product. The medication reached the market in January.
Earlier this yea…
Chain Drug Review - Schering-Plough gets okay to sell clarinex for allergies
January 7th, 2009 KENILWORTH, N.J. — Schering-Plough Corp. bas received Food and Drug Administration approval of Clarinex (desloratadine) for the treatment of seasonal allergic rhinitis (SAR).
The product builds upon the company’s heritage as a discoverer and developer of allergy and respiratory products as demonstrated by the success of its Claritin collection of nonsedating antihistamines and by Nasonex, a once-daily nasal st…
Chain Drug Review - OraSolv technology
January 2nd, 2009Cima Labs Inc. says OraSolv, its orally disintegrating drug delivery technology, will be incorporated in a version of Schering-Plough Corp.’s Clarinex Reditabs. Schering recently received FDA approval to market the product. The tablets disintegrate on the tongue without chewing or the need forwater.
Related Results
Cl…
Internal Medicine News - OTC antihistamine/decongestant
December 31st, 2008Clarinex-D 12 Hour is now available over the counter for relief of nasal and non-nasal symptoms of seasonal allergic rhinitis in patients aged 12 years and older. The tablets combine desloratadine (2.5 mg) with pseudoephe…
Drug Store News - Schering-Plough files Clarinex NDA
December 28th, 2008Schering-Plough, maker of the blockbuster antihistamine Claritin (loratadine) has filed a new drug application with the Food and Drug Administration to broaden the indication of its new drug Clarinex 5mg (desloratadine). Schering says Clarinex, positioned as a successor to the manufacturer’s blockbuster Claritin, currently t…
Drug Store News - Schering-Plough’s Clarinex receives more allergy indications
December 25th, 2008Schering-Plough’s Clarinex (desloratadine), positioned as a successor to Claritin (loratadine), received the green light from the FDA to be marketed as a treatment for allergic rhinitis. The new indication broadens the drug’s initial use as a treatment for seasonal allergic rhinitis. Expanded labeling for Clarinex also notes it can be used safely…
Chain Drug Review - Clarinex-D is cleared for treatment of allergies
December 20th, 2008The Food and Drug Administration has approved Clarinex-D, a nondrowsy antihistamine formulated with a decongestant. According to manufacturer Schering-Plough Corp., a unique gel control delivery system in the product provides effective 24-hour relief from symptoms of seasonal allergic rhinitis. The drug, av…
Knight Ridder/Tribune Business News - Blue Cross Pushes Claritin Alternative.
December 19th, 2008 By Deborah Crowe, Ventura County Star, Calif. Knight Ridder/Tribune Business News
Dec. 25–Thousand Oaks-based WellPoint Health Networks is distributing temporary discounts for a new over-the-counter Claritin alternative to Blue Cross…
Business Wire - Research and Markets: Benchmark Schering-Ploughs Performance against Key Rivals In The Ethical Pharmaceutical Sector
December 15th, 2008 DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c43905) has announced the addition of Schering-Plough: PharmaVitae Profile to their offering.
This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key …
Prevention Steps And Medications For Indoor Allergies
December 9th, 2008Antihistamines include older antihistamines, also called first-generation antihistamines, and newer second-generation antihistamines.
First-generation antihistamines most of these antihistamines are available without a prescription, such as diphenhydramine (Benadryl), clemastine (Tavist), and chlorpheniramine (Chlor-Trimeton Allergy). These older antihistamines are more likely to cause drowsiness. Depe…


